Literature DB >> 18346992

Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.

Earl S Ford1, Matthias B Schulze, Manuela M Bergmann, Claus Thamer, Hans-Georg Joost, Heiner Boeing.   

Abstract

OBJECTIVE: We sought to examine the association between plasma concentrations of liver enzymes gamma-glutamyltransferase (GGT) and alanine transaminase (ALT) and incident diabetes, prospectively. RESEARCH DESIGN AND METHODS: We conducted a case-cohort analysis of data from participants mainly aged 35-65 years in the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. The analytic sample included 787 participants with incident diabetes and 2,224 participants without diabetes.
RESULTS: Concentrations of GGT and ALT were significantly associated with incident diabetes after extensive adjustment. Compared with participants in the lowest quintile of GGT, the adjusted hazard ratios for increasing quintiles were 1.13 (95% CI 0.66-1.93), 1.67 (1.01-2.77), 2.77 (1.71-4.49), and 2.67 (1.63-4.37), respectively (P for linear trend <0.001). Compared with participants in the lowest quintile of ALT, the adjusted hazard ratios for incident diabetes were 0.93 (0.56-1.53) for quintile 2, 1.28 (0.83-1.96) for quintile 3, 1.35 (0.88-2.07) for quintile 4, and 1.93 (1.27-2.92) for quintile 5 (P for linear trend = 0.002). The magnitude of the associations were higher among men than women for GGT (P = 0.004) but did not differ significantly between men and women for ALT (P = 0.307).
CONCLUSIONS: Concentrations of GGT and ALT were significant predictors of incident diabetes in this study, even at concentrations still considered to be within the normal range.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346992     DOI: 10.2337/dc07-2159

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  36 in total

1.  Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes.

Authors:  Jukka Montonen; Dagmar Drogan; Hans-Georg Joost; Heiner Boeing; Andreas Fritsche; Erwin Schleicher; Matthias B Schulze; Tobias Pischon
Journal:  Eur J Epidemiol       Date:  2010-12-28       Impact factor: 8.082

2.  Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus.

Authors:  Yifei Zhang; Xi Lu; Jie Hong; Menglei Chao; Weiqiong Gu; Weiqing Wang; Guang Ning
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  Co-occurrence of obesity and patterns of alcohol use associated with elevated serum hepatic enzymes in US adults.

Authors:  James Tsai; Earl S Ford; Guixiang Zhao; Chaoyang Li; Kurt J Greenlund; Janet B Croft
Journal:  J Behav Med       Date:  2011-05-28

Review 4.  Prediabetes and associated disorders.

Authors:  Martin Buysschaert; José Luís Medina; Michael Bergman; Avni Shah; Jaqueline Lonier
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

5.  Association of changes in body mass index during earlier adulthood and later adulthood with circulating obesity biomarker concentrations in middle-aged men and women.

Authors:  J Montonen; H Boeing; E Schleicher; A Fritsche; T Pischon
Journal:  Diabetologia       Date:  2011-04-06       Impact factor: 10.122

6.  Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT.

Authors:  Cris A Slentz; Lori A Bateman; Leslie H Willis; A Tamlyn Shields; Charles J Tanner; Lucy W Piner; Victoria H Hawk; Michael J Muehlbauer; Greg P Samsa; Rendon C Nelson; Kim M Huffman; Connie W Bales; Joseph A Houmard; William E Kraus
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-16       Impact factor: 4.310

7.  Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease.

Authors:  Teruki Miyake; Teru Kumagi; Masashi Hirooka; Shinya Furukawa; Osamu Yoshida; Mitsuhito Koizumi; Shin Yamamoto; Takao Watanabe; Yasunori Yamamoto; Yoshio Tokumoto; Eiji Takeshita; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2016-03-12       Impact factor: 7.527

8.  Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.

Authors:  Teruki Miyake; Masashi Hirooka; Osamu Yoshida; Shinya Furukawa; Teru Kumagi; Mitsuhito Koizumi; Shin Yamamoto; Taira Kuroda; Eiji Arimitsu; Eiji Takeshita; Masanori Abe; Kohichiro Kitai; Bunzo Matsuura; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2016-06-24       Impact factor: 7.527

Review 9.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Authors:  Quentin M Anstee; Giovanni Targher; Christopher P Day
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-19       Impact factor: 46.802

10.  Liver enzymes, race, gender and diabetes risk: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A L C Schneider; M Lazo; C E Ndumele; J S Pankow; J Coresh; J M Clark; E Selvin
Journal:  Diabet Med       Date:  2013-04-12       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.